Major
Probable
描述
Methotrexate combined with warfarin increases bleeding risk and may cause enhanced anticoagulation; both drugs share protein-binding sites, amplifying free drug concentrations.
机制
Methotrexate displaces warfarin from albumin, raising free warfarin levels; warfarin may also reduce methotrexate clearance. Both drugs can impair hepatic function, affecting clotting factor synthesis.
临床意义
Serious bleeding events have been reported; concurrent hepatotoxicity risk adds further complexity to the interaction.
处理措施
Closely monitor INR and signs of bleeding; consider reducing warfarin dose empirically. Monitor liver function tests regularly.